Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 6, 2011, Pages 486-493

  Mimura, Yu ^a   Maruo, Yoshihiro ^a   Ohta, Yoriko ^a   Sato, Hiroshi ^a   Takeuchi, Yoshihiro ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYPROHEPTADINE; ESTRADIOL; GLUCURONOSYLTRANSFERASE; IMIPRAMINE; LAMOTRIGINE; PARACETAMOL; PROPOFOL;

ADVERSE OUTCOME; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; DRUG GLUCURONIDATION; DRUG SAFETY; ENZYME ACTIVITY; EXON; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ALLELES; ANIMALS; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; CRICETINAE; EXONS; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MUTATION, MISSENSE; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 81255160690     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00754.x     Document Type: Article

References (36)

1. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991;51:347-69.
2. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005;15:677-85.
3. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001;11:357-68.
4. King CD, Rios GR, Green MD, Tephly TR. UDP-glucurono syltransferases. Curr Drug Metab 2000;1:143-61.
5. Maruo Y, Takahashi H, Matsui K, Sato H, Takeuchi Y. Phase II drug metabolism and individualized drug therapy: a focus on functional genetic variation in UDP-glucuronosyltransferases. Curr Pharmacogenomics Person Med [Review] 2010;8:146-66.
6. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006;25:1659-72.
7. Sato H, Adachi Y, Koiwai O. The genetic basis of Gilbert's syndrome. Lancet 1996;347:557-8.
8. Maruo Y, Nishizawa K, Sato H, Doida Y, Shimada M. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999;103(6 Pt 1):1224-7.
9. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
10. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
11. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002;62:608-17.
12. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004;19:1023-8.
13. Ito M, Yamamoto K, Maruo Y, Sato H, Fujiyama Y, Bamba T. Effect of a conserved mutation in uridine diphosphate glucuronosyltransferase 1A1 and 1A6 on glucuronidation of a metabolite of flutamide. Eur J Clin Pharmacol 2002;58:11-4.
14. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 2005;33:672-5.
15. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 2008;103:131-6.
16. Alkharfy KM, Frye RF. Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. J Chromatogr B Analyt Technol Biomed Life Sci 2002;774:33-8.
17. Alkharfy KM, Frye RF. High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. J Chromatogr B Biomed Sci Appl 2001;753:303-8.
18. Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr Drug Metab 2005;6:91-9.
19. Guillemette C, De Vivo I, Hankinson SE, Haiman CA, Spiegelman D, Housman DE et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001;10:711-4.
20. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000;60:950-6.
21. Cecchin E, Russo A, Corona G, Campagnutta E, Martella L, Boiocchi M et al. UGT1A1*28 polymorphism in ovarian cancer patients. Oncol Rep 2004;12:457-62.
22. Kisaki O, Kato S, Shinohara K, Hiura H, Samori T, Sato H. High-throughput single-base mismatch detection for genotyping of UDP-glucuronosyltransferase (UGT1A1) with probe capture assay coupled with modified allele-specific primer extension reaction (MASPER). J Clin Lab Anal 2010;24:85-91.
23. Basu NK, Kubota S, Meselhy MR, Ciotti M, Chowdhury B, Hartori M and Owen IS. Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 2004;279:28320-29.
24. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A. Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 2008;73:611-20.
25. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007;11:525-48, vi.
26. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009;43:342-9.
27. Rauchschwalbe SK, Zuhlsdorf MT, Wensing G, Kuhlmann J. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ther 2004;42:73-7.
28. de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992;102:577-86.
29. Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.
30. Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007;62:690-701.
31. Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth 1998;8:491-9.
32. Green MD, Tephly TR. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 1998;26:860-7.
33. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34:1055-62.
34. Gaeta F, Alonzi C, Valluzzi RL, Viola M, Elia M, Romano A. Hypersensitivity to lamotrigine and nonaromatic anticonvulsant drugs: a review. Curr Pharm Des 2008;14:2874-82.
35. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075-81.
36. Xing Y, Yang L, Wang L, Shao L, Wei Z, Xuan J et al. Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics 2009;10:741-52.